Like most websites The Ophthalmologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subscribe to Newsletter
Subspecialties Retina, Basic & Translational Research

Improving on Anti-VEGF


Intravitreal administration of angiopoietin 1 (Ang1) may be more effective than anti-VEGF therapies in treating ischaemic retinal diseases, including retinopathy of prematurity (ROP) and proliferative diabetic retinopathy (PDR). Ang1 is a protein growth factor that promotes angiogenesis.

Junyeop Lee and colleagues at the Korea Advanced Institute of Science and Technology injected recombinant chimeric Ang1 protein into the retinas of mice with oxygen-induced retinopathy (OIR), a mouse model of ischemic retinopathy. OIR mimics features of ROP and PDR: the retinas of affected mice develop extensive vascular regression in the central region and abnormal neovascular tuft in the middle and peripheral region. A single intravitreal injection suppressed vascular leakage, stimulated the formation of healthy blood vessels in avascular regions, and protected retinal neurons from damage, within one week.

These results suggest that therapies based on Ang1 could be more effective than VEGF-Trap in reversing ischemic retinal diseases. Anti-VEGF therapies require repeated intraocular injections and are associated with neuronal damage. Ang1 administration suppressed NVT formation to a greater extent than VEGF-Trap, reducing the average area of the avascular region by 75 percent. It also improved the vascular network in the deep layer of the retina, a benefit that wasn’t achieved with VEGF-Trap.

“Our study indicates that, unlike anti–VEGF-A therapies, intravitreal Ang1 can induce healthy and functional angiogenesis and consequently prevent retinal neuronal damage due to ischemic injury,” the researchers wrote in a paper published in Science Translational Medicine. “Electrophysiological analyses demonstrated that Ang1 protected retinal neuronal function from ischemic injuries, whereas VEGF-Trap did not.” The team hopes that Ang1 can be established as a treatment strategy that focuses on “the true recovery of the injured organ, rather than merely delaying disease progression.”

Receive content, products, events as well as relevant industry updates from The Ophthalmologist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. J. Lee, K. E. Kim, D. K. Choi, et al., “Angiopoietin-1 Guides Directional Angiogenesis Through Integrin ?v?5 Signaling for Recovery of Ischemic Retinopathy”, Sci Transl Med. 5(203), 203ra127 (2013).
About the Author
Sophia Ktori

I have 22 years' experience as a writer and editor specializing in pharmaceuticals, biotechnology, medicine and life sciences. I was also European News Editor at GEN for 7 years, reporting daily on academic research, and the commercial aspects of the biotech and pharma industries. A brief, postgrad period during which I was involved in molecular genetics research at Bristol University in the 1980s is a more distant memory, and most of what I achieved in then is now automated and can be completed within days. 

Related Product Profiles
Uncover the Unique DNA of SPECTRALIS®

| Contributed by Heidelberg Engineering

Subspecialties Retina
ForeseeHome® – remote monitoring to help detect wet AMD earlier and improve outcomes

| Contributed by Notal Vision

Product Profiles

Access our product directory to see the latest products and services from our industry partners

Most Popular
Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine